TABLE 1.
Antiviral activity (IC50) of peptides in single-cycle assay in HT1080/ACE2 and A549/ACE2 cells infected with pseudoviruses (NL4-3ΔEnv-NanoLuc/SARS-CoV-2 and NL4-3.Luc.R-E-/VSV-G) and cytotoxicity (CC50)
| Peptide | HT1080/ACE2 cells |
A549/ACE2 cells |
||||
|---|---|---|---|---|---|---|
| IC50 (μM)a |
CC50 (μM)a | IC50 (μM)a |
CC50 (μM)a | |||
| SARS-CoV-2 | VSV-G | SARS-CoV-2 | VSV-G | |||
| NYBSP-1 | 4.1 ± 0.26 | >27.5 | >27.5b | 2.2 ± 0.14 | >27.5 | >27.5b |
| NYBSP-2 | 2.9 ± 0.27 | >26.8 | >26.8b | 2.68 ± 0.14 | >26.8 | >26.8b |
| NYBSP-3 | 12.9 ± 0.35 | >27.6 | >27.6b | ∼25 | >27.6 | >27.6b |
| NYBSP-4 | 1.97 ± 0.14 | >26.6 | >26.6b | 2.8 ± 0.08 | >26.6 | >26.6b |
| NYBSP-Cc | >27.7 | >27.7 | >27.7b | >27.7 | >27.7 | >27.7b |
| StRIP16d | >43.5 | >43.5 | >43.5b | >43.5 | >43.5 | >43.5b |
| Anti-ACE2 | <70 ng/ml | >5 μg/ml | >5 μg/mlb | <70 ng/ml | >5 μg/ml | >5 μg/mlb |
a
The reported IC50 and CC50 values represent the means ± standard deviations (n = 3).
b
Less than 10% toxicity at this dose.
c
NYBSP-C, a linear peptide from Helix-1, was used as a control.
d
StRIP16, an ACE2-unrelated Rab8a GTPase-binding double-stapled peptide reported earlier (29), was used as a control.